drugset / Trial / NCT04195399
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Phase 2
Active not recruiting
31 enrolled
Children's Oncology Group
National Cancer Institute (NCI) · collabSpringWorks Therapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2020-10-07
- Primary completion
- 2026-03-31
- Completion
- 2027-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirogacestat | Small molecule | — | Oral |